Skip to main content

Advertisement

Table 2 Baseline characteristics of those aged 65-80, by treatment: age, sex, race, height, weight, BMI and medication use.

From: Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

    All First randomization Second randomization
     PRM Placebo PRM Placebo
   N 281 137 144 198 75
Characteristic Visit       
Age (years) 1 Mean (SD) 71.0 (4.1) 71.1 (3.8) 70.9 (4.4) 70.9 (3.9) 70.9 (4.4)
Sex   N (%) female 182 (64.8%) 89 (65.0%) 93 (64.6%) 128 (64.6%) 50 (66.7%)
Race*   N (%) white 280 (100.0%) 137 (100.0%) 143 (100.0%) 198 (100.0%) 74 (100.0%)
Height (m) 1 Mean (SD) 1.65 (0.09) 1.65 (0.09) 1.64 (0.09) 1.65 (0.09) 1.64 (0.09)
Weight (kg) 1 Mean (SD) 73.3 (13.0) 73.1 (14.1) 73.6 (11.8) 73.2 (13.2) 74.1 (12.6)
BMI (kg/m2) 1 Mean (SD) 27.0 (3.8) 26.8 (3.6) 27.3 (3.9) 26.8 (3.6) 27.7 (4.2)
Taking any medications 1 N (%) 265 (94.3%) 130 (94.9%) 135 (93.8%) 187 (94.4%) 70 (93.3%)
Taking codeine† 1 N (%) 73 (26.2%) 35 (25.7%) 38 (26.6%) 50 (25.5%) 20 (26.7%)
Taking codeine 2 N (%) 58 (20.6%) 28 (20.4%) 30 (20.8%) 40 (20.2%) 16 (21.3%)
Confirmed codeine analgesic 2 N (%) 43 (15.3%) 18 (13.1%) 25 (17.4%) 25 (12.6%) 16 (21.3%)
  1. *One patient missed observation
  2. †Two patients missed observations at Visit 1
  3. PRM, prolonged release melatonin; SD, standard deviation